Login to Your Account



Merck, Actelion Enter Potential $272M Deal On Renin Inhibition

By Randall Osborne


Friday, December 5, 2003
In its second deal of the week, Merck & Co. Inc. tapped Swiss firm Actelion Inc. for a potential $272 million agreement to develop new classes of renin inhibitors for cardio-renal diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription